PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.59%
Cash & equivalents declining -7.59% while Biotechnology shows -0.99% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Cash + STI yoy growth 1.25-1.5x the Biotechnology median of -5.65%. Mohnish Pabrai might see a strategic surplus if short-term returns make sense.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Exceeding 1.5x Biotechnology median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-8.57%
Current assets growth ≥ 1.5x the Biotechnology median of -3.26%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-5.56%
PP&E growth ≥ 1.5x the Biotechnology median of -0.81%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.97%
≥ 1.5x the Biotechnology median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Below half the Biotechnology median of 0.00%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
≥ 1.5x the Biotechnology median of -2.14%. Joel Greenblatt sees more aggressive asset expansion than peers, but must confirm returns are adequate.
-2.42%
Payables growth above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
3.64%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
No Data
No Data available this quarter, please select a different quarter.
-101.55%
Below half Biotechnology median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
-3.64%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-2.05%
Below half Biotechnology median of 1.33%. Joel Greenblatt sees more conservative short-term leverage than peers.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.51%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects major expansions in deferred taxes.
No Data
No Data available this quarter, please select a different quarter.
-0.32%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-0.65%
Below half Biotechnology median of 0.43%. Joel Greenblatt sees a much lower liability expansion vs. peers.
3.70%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects heavier share issuance than peers.
-2.84%
0.75-0.9x Biotechnology median of -3.43%. John Neff wonders if the firm lags peers in reinvested profits.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.53%
≥ 1.5x Biotechnology median of -5.46%. Joel Greenblatt sees stronger equity growth vs. peers.
-8.43%
≥ 1.5x Biotechnology median of -2.11%. Joel Greenblatt sees more aggressive expansions than peers.
0.97%
≥ 1.5x Biotechnology median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-4.43%
Above 1.5x Biotechnology median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
7.68%
Above 1.5x Biotechnology median 4.05%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.